UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

시가총액

$628M

수익

$90M

P/E 비율

N/A

주가순자산비율

-51.87

부채자본비율

-14.02

배당 수익률

0.00%

PEG 비율

0.22

순이익

-$127M

순이익률

-140.35%

Beta

0.398

매출 총이익

0.90%

주가매출비율

5.05

52주 최저가

$0.00

52주 최고가

$0.00

마지막 업데이트: June 30 at 19:40:56